Northwest Bioth Cmn (NWBO): Price and Financial Metrics

NWBO POWR Grades

• Growth is the dimension where NWBO ranks best; there it ranks ahead of 81.78% of US stocks.
• The strongest trend for NWBO is in Momentum, which has been heading down over the past 45 weeks.
• NWBO ranks lowest in Momentum; there it ranks in the 11th percentile.

NWBO Stock Summary

• NWBO's price/sales ratio is 831.8; that's higher than the P/S ratio of 99.1% of US stocks.
• Equity multiplier, or assets relative to shareholders' equity, comes in at -0.09 for Northwest Biotherapeutics Inc; that's greater than it is for just 5.68% of US stocks.
• Over the past twelve months, NWBO has reported earnings growth of 799.77%, putting it ahead of 97.16% of US stocks in our set.
• Stocks with similar financial metrics, market capitalization, and price volatility to Northwest Biotherapeutics Inc are VLDR, UCL, WIMI, QNST, and CNET.
• NWBO's SEC filings can be seen here. And to visit Northwest Biotherapeutics Inc's official web site, go to www.nwbio.com.

NWBO Valuation Summary

• NWBO's price/earnings ratio is -2.4; this is 106.58% lower than that of the median Healthcare stock.
• Over the past 239 months, NWBO's price/sales ratio has gone up 173.7.
• NWBO's price/sales ratio has moved up 173.7 over the prior 239 months.

Below are key valuation metrics over time for NWBO.

NWBO Growth Metrics

• Its 4 year cash and equivalents growth rate is now at -93.86%.
• The 3 year revenue growth rate now stands at -65.24%.
• The 4 year net income to common stockholders growth rate now stands at 104.54%.

Over the past 33 months, NWBO's revenue has gone up $479,000.

The table below shows NWBO's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2021-06-30	1.374	-38.265	-474.108
2021-03-31	0.96	-37.802	-536.47
2020-12-31	1.291	-32.093	-529.821
2020-09-30	1.685	-27.868	-242.649
2020-06-30	2.062	-26.298	-54.795
2020-03-31	2.641	-29.647	3.376

NWBO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• NWBO has a Quality Grade of C, ranking ahead of 29.4% of graded US stocks.
• NWBO's asset turnover comes in at 0.045 -- ranking 330th of 677 Pharmaceutical Products stocks.
• EDSA, BLCM, and BMRN are the stocks whose asset turnover ratios are most correlated with NWBO.